Overview

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2023-01-27

Target enrollment:

Participant gender:

Summary

The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

ADC Therapeutics S.A.

Treatments:

Loncastuximab tesirine